Cargando…

β-lactam Resistance in Pseudomonas aeruginosa: Current Status, Future Prospects

Pseudomonas aeruginosa is a major opportunistic pathogen, causing a wide range of acute and chronic infections. β-lactam antibiotics including penicillins, carbapenems, monobactams, and cephalosporins play a key role in the treatment of P. aeruginosa infections. However, a significant number of isol...

Descripción completa

Detalles Bibliográficos
Autores principales:	Glen, Karl A., Lamont, Iain L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706265/ https://www.ncbi.nlm.nih.gov/pubmed/34959593 http://dx.doi.org/10.3390/pathogens10121638

Ejemplares similares

1600. Susceptibility of β-Lactam-Resistant Pseudomonas aeruginosa to Other β-Lactams: Is There Truly a Lack of Cross-Resistance?
por: Patel, Twisha S, et al.
Publicado: (2019)

Co-regulation of β-lactam resistance, alginate production and quorum sensing in Pseudomonas aeruginosa
por: Balasubramanian, Deepak, et al.
Publicado: (2011)

Murepavadin induces envelope stress response and enhances the killing efficacies of β-lactam antibiotics by impairing the outer membrane integrity of Pseudomonas aeruginosa
por: Wei, Xiaoya, et al.
Publicado: (2023)

Mortality in patients with carbapenem-resistant Pseudomonas aeruginosa with and without susceptibility to traditional antipseudomonal β-lactams
por: Howard-Anderson, Jessica, et al.
Publicado: (2021)

Trimeric Tobramycin/Nebramine Synergizes β-Lactam Antibiotics against Pseudomonas aeruginosa
por: Dhiman, Shiv, et al.
Publicado: (2023)

Relation between Resistance to Antipseudomonal β-Lactams and ampC and mexC Genes of Pseudomonas aeruginosa
por: Rezaei, Fatemeh, et al.
Publicado: (2016)

Regulation of AmpC-Driven β-Lactam Resistance in Pseudomonas aeruginosa: Different Pathways, Different Signaling
por: Torrens, Gabriel, et al.
Publicado: (2019)

1601. Evaluation of Synergy with β-Lactams Plus Aztreonam Against Pseudomonas aeruginosa (PSA)
por: O’Donnell, J Nicholas, et al.
Publicado: (2019)

Activity of newest generation β-lactam/β-lactamase inhibitor combination therapies against multidrug resistant Pseudomonas aeruginosa
por: Haines, Robbie R., et al.
Publicado: (2022)

In vitro activity of cefiderocol against Pseudomonas aeruginosa demonstrating evolved resistance to novel β-lactam/β-lactamase inhibitors
por: Shields, Ryan K, et al.
Publicado: (2023)

Aminoglycoside-Modifying Enzymes Are Sufficient to Make Pseudomonas aeruginosa Clinically Resistant to Key Antibiotics
por: Thacharodi, Aswin, et al.
Publicado: (2022)

Ceftazidime resistance in Pseudomonas aeruginosa is multigenic and complex
por: Ramsay, Kay A., et al.
Publicado: (2023)

600. β-Lactam Resistance Mechanisms in Pseudomonas aeruginosa Isolates Analyzed Using Whole-Genome Sequencing (WGS) and Transcriptions Analysis and Their Impact in Resistance to New β-Lactam/β-Lactamase Inhibitors
por: Castanheira, Mariana, et al.
Publicado: (2019)

In host evolution of beta lactam resistance during active treatment for Pseudomonas aeruginosa bacteremia
por: Spottiswoode, Natasha, et al.
Publicado: (2023)

Activity of novel β-lactam/β-lactamase inhibitor combinations against serine carbapenemase-producing carbapenem-resistant Pseudomonas aeruginosa
por: Lee, Su Young, et al.
Publicado: (2023)

Catalytic Spectrum of the Penicillin-Binding Protein 4 of Pseudomonas aeruginosa, a Nexus for the Induction of β-Lactam Antibiotic Resistance
por: Lee, Mijoon, et al.
Publicado: (2014)

722. Risk Factors for Infection or Colonization with Ceftolozane/Tazobactam Non-Susceptible Extensively β-Lactam Resistant Pseudomonas aeruginosa
por: Lee, Michelle, et al.
Publicado: (2023)

Molecular Mechanism of the β-Lactamase Mediated β-Lactam Antibiotic Resistance of Pseudomonas aeruginosa Isolated From a Chinese Teaching Hospital
por: Lin, Hailong, et al.
Publicado: (2022)

2125. Activity of Novel β-Lactam/β-Lactamase Inhibitor Combinations against Serine-Carbapenemase producing Carbapenem-Resistant Pseudomonas aeruginosa
por: Lee, Su Young, et al.
Publicado: (2023)

834. Clinical Outcomes with Carbapenem-Resistant Pseudomonas aeruginosa that Retain Susceptibility to Traditional Antipseudomonal β-lactams: Atlanta, 2016-2018
por: Howard-Anderson, Jessica, et al.
Publicado: (2020)

YgfB increases β-lactam resistance in Pseudomonas aeruginosa by counteracting AlpA-mediated ampDh3 expression
por: Eggers, Ole, et al.
Publicado: (2023)

2269. Clinical Outcomes in Patients with Carbapenem-Non-Susceptible, β-Lactam-Susceptible Pseudomonas aeruginosa Infections
por: Gavaghan, Victoria M, et al.
Publicado: (2019)

Loss of membrane‐bound lytic transglycosylases increases outer membrane permeability and β‐lactam sensitivity in Pseudomonas aeruginosa
por: Lamers, Ryan P., et al.
Publicado: (2015)

The PitA protein contributes to colistin susceptibility in Pseudomonas aeruginosa
por: Erdmann, Mareike B., et al.
Publicado: (2023)

The Emergence and Dissemination of Multidrug Resistant Pseudomonas aeruginosa in Lebanon: Current Status and Challenges during the Economic Crisis
por: Dabbousi, Ahmad Ayman, et al.
Publicado: (2022)

Analysis of Metallo-β-lactamases, oprD Mutation, and Multidrug Resistance of β-lactam Antibiotic-Resistant Strains of Pseudomonas aeruginosa Isolated from Southern China
por: Li, Fei, et al.
Publicado: (2020)

Resistance of Pseudomonas Aeruginosa
por: Graevenitz, Alexander Von
Publicado: (1977)

New β-Lactam Antibiotics and Ceragenins – A Study to Assess Their Potential in Treatment of Infections Caused by Multidrug-Resistant Strains of Pseudomonas aeruginosa
por: Paprocka, Paulina, et al.
Publicado: (2021)

PBP Target Profiling by β-Lactam and β-Lactamase Inhibitors in Intact Pseudomonas aeruginosa: Effects of the Intrinsic and Acquired Resistance Determinants on the Periplasmic Drug Availability
por: Montaner, Maria, et al.
Publicado: (2022)

Meropenem/Vaborbactam: β-Lactam/β-Lactamase Inhibitor Combination, the Future in Eradicating Multidrug Resistance
por: Duda-Madej, Anna, et al.
Publicado: (2023)

Penetration through Outer Membrane and Efflux Potential in Pseudomonas aeruginosa of Bulgecin A as an Adjuvant to β-Lactam Antibiotics
por: Kim, Choon, et al.
Publicado: (2023)

The Current Status and Future Perspectives of Beta-Lactam Therapeutic Drug Monitoring in Critically Ill Patients
por: Novy, Emmanuel, et al.
Publicado: (2023)

Outcomes of adult patients in the intensive care unit with Pseudomonas aeruginosa pneumonia who received an active anti‐pseudomonal β‐lactam: Does “S” equal success in the presence of resistance to other anti‐pseudomonal β‐lactams?
por: Lodise, Thomas P., et al.
Publicado: (2021)

Bulgecin A as a β-lactam enhancer for carbapenem-resistant Pseudomonas aeruginosa and carbapenem-resistant Acinetobacter baumannii clinical isolates containing various resistance mechanisms
por: Skalweit, Marion J, et al.
Publicado: (2016)

The Intriguing Carbapenemases of Pseudomonas aeruginosa: Current Status, Genetic Profile, and Global Epidemiology
por: Hammoudi Halat, Dalal, et al.
Publicado: (2022)

Drugs That Changed Society: History and Current Status of the Early Antibiotics: Salvarsan, Sulfonamides, and β-Lactams
por: Christensen, Søren Brøgger
Publicado: (2021)

Antipseudomonal β-Lactams Resistance in Iran
por: Rabiei, Mohammad Mahdi, et al.
Publicado: (2020)

Performance of Antipseudomonal β-Lactams on the Accelerate PhenoTest BC Kit against a Collection of Pseudomonas aeruginosa Isolates
por: Sikorski, Aaron, et al.
Publicado: (2021)

Current status of β-lactam antibiotic use and characterization of β-lactam-resistant Escherichia coli from commercial farms by integrated broiler chicken operations in Korea
por: Jung, Hye-Ri, et al.
Publicado: (2023)

Effectiveness of empiric aztreonam compared to other beta-lactams for treatment of Pseudomonas aeruginosa infections
por: Hogan, Michael, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_0h7r08cnaet3ca63u4gl6n87ua